{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-009664","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.668350+00:00","generated_at":"2026-06-06T09:46:03.305911+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cellectar reports share count update after warrant exercises; 30.45M common shares outstanding as of Jan 31, 2024","bullets":["Common shares outstanding: 30,452,042 as of January 31, 2024, up from prior count due to Tranche A and other warrant exercises since November 2023.","Preferred stock outstanding: 319.76 Series E-2, 918.00 Series E-3, and 111 Series D preferred shares.","Warrant exercises increased share count, diluting existing common stockholders.","No business updates or financial results provided; filing solely updates capital structure."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-009664","json":"https://secwatch.observer/filing/0001104659-24-009664.json","markdown":"https://secwatch.observer/filing/0001104659-24-009664.md","text":"https://secwatch.observer/filing/0001104659-24-009664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924009664/0001104659-24-009664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924009664/tm244672d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:46:03.305911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}